Trial reportEuropean journal of nuclear medicine and molecular imaging2018
Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
Trial report in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 57 citations in OpenAlex.
- Cutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughs.European journal of nuclear medicine and molecular imaging · 2026Review
- Predicting Remaining Survival of Glioblastoma Patients with Radiomics Analysis Based onCancers · 2025Article
- The role of FET-PET in patient selection and response assessment for reirradiation in recurrent glioblastoma.Frontiers in oncology · 2025Review
- Contribution of [Pharmaceuticals (Basel, Switzerland) · 2024Review
- Amino acid PET vs. RANO MRI for prediction of overall survival in patients with recurrent high grade glioma under bevacizumab therapy.European journal of nuclear medicine and molecular imaging · 2024Article
- PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.The Lancet. Oncology · 2024Review
- Review
- Boosting the acceptance ofEuropean journal of nuclear medicine and molecular imaging · 2023Article
- Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.European journal of nuclear medicine and molecular imaging · 2023Article
- Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.Neuro-oncology · 2023Article
- Assessment and prediction of glioblastoma therapy response: challenges and opportunities.Brain : a journal of neurology · 2023Article
- Article
- Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy.Advanced drug delivery reviews · 2022Review
- The Use ofDiagnostics (Basel, Switzerland) · 2022Review
- PET/MR in recurrent glioblastoma patients treated with regorafenib: [The British journal of radiology · 2022Observational
- Repeatability of image features extracted from FET PET in application to post-surgical glioblastoma assessment.Physical and engineering sciences in medicine · 2021Article
- Conventional and advanced imaging throughout the cycle of care of gliomas.Neurosurgical review · 2021Review
- Redo craniotomy or bevacizumab for symptomatic steroid-refractory true or pseudoprogression following IMRT for glioblastoma.Neuro-oncology practice · 2021Article
- Review
- TERT-Promoter Mutational Status in Glioblastoma - Is There an Association With Amino Acid Uptake on DynamicFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe goal of this prospective study was to compare the value of both conventional MRI and O-(2-
methodsAfter chemoradiation with concomitant and adjuvant temozolomide, 21 IDH wild-type glioblastoma patients at first progression (age range, 33-75 years; MGMT promoter unmethylated, 81%) were treated with BEV/LOM. Contrast-enhanced MRI and FET-PET scans were performed at baseline and after 8-10 weeks. We obtained FET metabolic tumor volumes (MTV) and tumor/brain ratios. Threshold values of FET-PET parameters for treatment response were established by ROC analyses using the post-progression overall survival (OS) ≤/>9 months as the reference. MRI response assessment was based on RANO criteria. The predictive ability of FET-PET thresholds and MRI changes on early response assessment was evaluated subsequently concerning OS using uni- and multivariate survival estimates.
resultsEarly treatment response as assessed by RANO criteria was not predictive for an OS>9 months (P = 0.203), whereas relative reductions of all FET-PET parameters significantly predicted an OS>9 months (P < 0.05). The absolute MTV at follow-up enabled the most significant OS prediction (sensitivity, 85%; specificity, 88%; P = 0.001). Patients with an absolute MTV below 5 ml at follow-up survived significantly longer (12 vs. 6 months, P < 0.001), whereas early responders defined by RANO criteria lived only insignificantly longer (9 vs. 6 months; P = 0.072). The absolute MTV at follow-up remained significant in the multivariate survival analysis (P = 0.006).
conclusionsFET-PET appears to be useful for identifying responders to BEV/LOM early after treatment initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.